[Effect of RGD-containing peptides on platelet aggregation]

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• Platelet aggregation plays a crucial role in thrombosis and hemostasis.
• Understanding the molecular mechanisms of platelet activation is vital for developing anti-thrombotic therapies.
• Peptides derived from viral proteins can offer insights into platelet-interacting motifs.

Purpose of the Study:

• To investigate the anti-platelet aggregation activity of novel synthetic peptides ARGDS-NH2 and RGD-dFK.
• To compare the efficacy of these synthetic peptides with a known inhibitor, pentoxifylline.
• To evaluate the influence of a viral peptide fragment (VPNLRGDLQVLA) on platelet aggregation.

Main Methods:

• In vitro study of human platelet aggregation induced by adenosine diphosphate (ADP).
• Synthesis of peptides ARGDS-NH2 and RGD-dFK via fermentative methods.
• Administration of varying peptide concentrations (0.1-10 mM) to assess dose-dependent effects.

Main Results:

• All tested peptides, including VPNLRGDLQVLA, inhibited ADP-induced human platelet aggregation.
• Synthetic peptides ARGDS-NH2 and RGD-dFK exhibited the most significant inhibitory effects.
• At equivalent concentrations, ARGDS-NH2 and RGD-dFK demonstrated superior inhibition compared to pentoxifylline.

Conclusions:

• Novel synthetic peptides ARGDS-NH2 and RGD-dFK are potent inhibitors of human platelet aggregation.
• These synthetic peptides hold promise as potential therapeutic agents for thrombotic disorders.
• Further research into the mechanism of action and in vivo efficacy of these peptides is warranted.